Global leader in assay solutions releases signal amplification system
to improve sensitivity in automated detection of cellular events to
speed disease and therapeutic research
WALTHAM, Mass.--(BUSINESS WIRE)--
PerkinElmer,
Inc., a global leader focused on improving the health and safety of
people and the environment, today announced the release of the HCA
ImagAmp™ reagent kit for high content screening and analysis
applications in life sciences and drug discovery research.
High content analysis (HCA), also known as image cytometry, is a
powerful tool for automated cell biology that allows unbiased imaging
and analysis of cellular samples. The technique is widely used in a
variety of research areas including cell differentiation, cell toxicity,
programmed cell death, drug discovery, protein expression and signaling
pathway analysis.
"The new HCA ImagAmp reagent kit is designed to allow researchers to
measure proteins of interest that were previously undetectable using
standard methods of detection in high content screening," said Martina
Bielefeld-Sévigny, PhD, vice president and general manager,
Bio-discovery, PerkinElmer. "For instance, the sensitivity enhancement
provided by HCA ImagAmp technology enables earlier detection of critical
cellular events such as apoptosis, speeding disease and therapeutic
research."
Flexible and efficient, the HCA ImagAmp™ platform offers faster
detection with high quality imaging capability, along with easy to use
features for integrating into workflows. The kits leverage PerkinElmer's
proprietary Tyramide
Signal Amplification™ (TSA) technology to deliver unprecedented
sensitivity without compromising image resolution. HCA ImagAmp
technology can be added to virtually any assay protocol with a simple
10-minute incubation step. The HCA ImagAmp kits are designed to allow
researchers to achieve consistent detection of weakly expressed targets
and reach their HCS research goals sooner. The new kits are
platform-agnostic and designed to provide superior image resolution on
virtually any high content screening instrument, including PerkinElmer's Opera®and Operetta®Imaging Systems.
Key features of the HCA ImagAmp technology enable end-users to:
-
Quantify analytes of interest at previously undetectable levels
-
Extend quantitative range and improve reliability of results
-
Conserve primary antibody while improving assay specificity
-
Reduce exposure time for higher throughput
-
Enhance image resolution with robust signal
To learn more, please visit: www.perkinelmer.com\HCAImagAmp.
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and
safety of people and the environment. The Company reported revenue of
approximately $1.7 billion in 2010, has about 6,200 employees serving
customers in more than 150 countries, and is a component of the S&P 500
Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
Edelman (on behalf of PerkinElmer, Inc.)
Amanda L. Connolly,
404-832-6785
amanda.connolly@edelman.com
Source: PerkinElmer, Inc.
News Provided by Acquire Media